A Growing Market

The market for transdermal drug delivery has been growing at a robust pace in recent years. According to a 2014 research report from Kelly Scientific (“Global Transdermal Drug Delivery Market to 2017”), while oral delivery still represents the largest share of such markets globally, transdermal is the fastest growing.

The growth in transdermal delivery is driven by a number of factors, including:

  • oral medications are largely broken down in passage through the gastrointestinal tract, leaving less of the active ingredient available for systemic delivery to address the intended issue;
  • common and reputed side effects of oral medications, including stomach upset, liver and kidney problems, hypertension, etc.;
  • greater safety and efficacy of topicals versus orals;
  • targeted delivery of active ingredients which is possible with topical but not with oral medications;
  • new technologies that can deliver a broader range of molecules transdermally; and
  • as the patents for popular drugs expire, manufacturers are looking for ways to reposition and re-energize growth due to competition from generic competitors.

Our Unique System

The foundation of the Delivra business is its unique and patent-pending transdermal delivery system, which has the capability to deliver a very broad range of pharmaceutical and natural molecules through the skin.

Delivra has 21 Natural Health Product (NHP) registrations with Health Canada, and 11 National Drug Code (NDC) registrations with US FDA. We also have a growing intellectual property portfolio, with 8 patents-pending, on our delivery system and specific applications of our delivery system.

Some of the unique features and benefits of the Delivra transdermal system include:

  • Very strong dermal absorption and deep penetration
  • Polypharmacy and multi-drug formulations (base can hold up to 25% active molecules)
  • Delivery of larger molecules (~1400 Da), water-soluble molecules, peptides, etc.
  • Local or systemic delivery
  • Controlled (“slow”) release of actives
  • Mitigation of “depot effect” with lipophilic molecules

Our dedicated R&D team works out of a state of the art lab facility in Charlottetown, PEI, Canada.

We follow stringent scientific protocols in establishing efficacy and safety in everything we do.

We have extensive experience in pre-clinical and clinical research; including analytical, bioanalytical chemistry and molecular biology, in vitro bioassays, immunology, formulations, bioactive synthesis, pharmacology, proteomics, etc.